期刊文献+

4-(4-氨基苯基)-3-吗琳酮的合成 被引量:2

Synthesis of 4-( 4-aminophenyl)-3-morpholinone
原文传递
导出
摘要 目的改进利伐沙班关键中间体4-(4-氨基苯基)-3-吗琳酮(Ⅰ)的合成方法。方法将溴苯(Ⅱ)先硝化再与乙醇胺反应后依次经氯乙酰化、还原得到2-[2-氯-N-(4-氨基苯基)乙酰胺基]乙基2-氯乙酸酯(Ⅵ);中间体Ⅵ在碱性条件下环合制得Ⅰ;或经叔丁氧羰基保护、环合,再在浓盐酸作用下脱除叔丁氧羰基保护基制得Ⅰ。结果目标化合物的结构经1HNMR确证,上述两种方法的总收率分别为26.6%、19.0%。结论所用方法具有反应步骤少、原料易得、条件温和、操作简便、收率较高等优点。 OBJECTIVE To improve the method for the synthesis of 4 - (4 - aminophenyl) - 3 - morpholinone ( Ⅰ ). METHODS Bromobenzene ( Ⅱ ) underwent a sequence of reactions of nitration, N- arylation, acylation, reduction and cyclization, and yielded that 2 - [ N - (4 - aminobenzene) - 2 - chloroacetamido ] ethyl - 2 - chloroacetate ( Ⅵ). Compound I was prepared from intermediate VI via cyclization under alkdine condition. Or from di - t - butyl dicarbonate protected Ⅵ via cyclization, and then deproteetion of tert - butyloxy - carbonyl group in the presence of concentrated hydrochloric acid. RESULTS The chemical structure of 4 - (4 - aminophe- nyl) -3 -morpholinone was determined bylHNMR. The overall yields of these two methods were about 26. 6% and 19.0%, respectively. CONCLUSION The method has the advantages of fewer reaction steps materials obtained easily, milder reaction condi- tion, easier operation and higher yield.
出处 《华西药学杂志》 CAS CSCD 2015年第6期642-644,共3页 West China Journal of Pharmaceutical Sciences
关键词 4-(4-氨基苯基)-3-吗啉酮 利伐沙班 2-[2-氯-N-(4-氨基苯基)乙酰胺基]乙基2-氯乙酸酯 中间体 合成 4 - ( 4 - aminophenyl) - 3 - morpholinone Rivaroxaban 2 - [ N - ( 4 - aminobenzene ) - 2 - chloroacetamido ] ethyl - 2 - eh|oroacetate Intermediate Synthesis
  • 相关文献

参考文献6

二级参考文献31

  • 1张翠娥,陈兴泉,刘鸿.对硝基苯乙酸还原反应的研究[J].应用化工,2004,33(4):55-56. 被引量:6
  • 2Wei DENG Ye Feng WANG Chen ZHANG Lei LIU Qing Xiang GUO.CuI/Proline-catalyzed N-Arylation of Nitrogen Heterocycles[J].Chinese Chemical Letters,2006,17(3):313-316. 被引量:2
  • 3路新华,郑智慧,马瑛,石英,董悦生,任晓,穆栋,张华,贺建功.微生物来源的Xa因子抑制剂F02-2172的研究[J].中国抗生素杂志,2007,32(5):277-279. 被引量:9
  • 4European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]. http://www. emea. europa. eu/humandoes/PDFs/EPAR/xareho/H-94-en1. pdf 被引量:1
  • 5European Medicines Agency. European Public Assessment Report (EPAR) Xarelto, EMEA/H/C/944 [ EB/OL ]. [ 2008 - 10 - 11 ]., http://www. emea. europa, eu/humandocs/Humans/EPAR/xarelto/xarelto. htm. 被引量:1
  • 6ROEHRIG S, STRAUB A, POHLMANN J. Discovery of the novel antithrombotic agent 5 -chloro-N- ( │( 5 S ) -2-ox0-3 - [ 4- ( 3 -oxomorpholin-4-yl) phenyl ] -1,3-oxazolidin-5-yl │ methyl ) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[ J]. J Med Chem,2005,48 ( 19 ) :5900 - 5908. 被引量:1
  • 7DAURE EW, FUJIKAWA K, KISIEL W. The coagulation cascude: Initiation, maintenance and regulation [ J ]. Biochemistry, 1991,30(43) :10363 - 10370. 被引量:1
  • 8WEINZ C, BUETEHORN U,DAEHLER HP, et al. Pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in rats and dogs [ J ]. Xenobiotica, 2005,35 ( 9 ) : 891 -910 被引量:1
  • 9KUBITZA D, BECKA M, ZUEHLSDOR M, et al. Effect of Food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban) , an oral, direct factor Xa inhibitor, in healthy subjects [ J ]. J Clin Pharm, 2006,46 ( 6 ) : 549 - 558. 被引量:1
  • 10LASSEN MR, TUPRPIE AG, ROSENCHER N, et al. Rivaroxaban an oral, direct factor Xa inhibitor for thromboprophylaxis after totalknee arthroplasty: The RECORD3 Trial. (Abstract No.308). American Society of Hematology. 49th Annual Meeting. Atlanta. December 2007 [ EB/OL]. [ 2007 - 11 - 16 ]. http:// www. abstracts2view. com/hem07/view. php? nu = HEM07L1-2447. 被引量:1

共引文献18

同被引文献15

  • 1孙炳峰,林国强.4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途[P].CNl02320988A,2011-06-03. 被引量:2
  • 2Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor [ J ]. Expert Opin Investig Drugs ,2008 ; 17:925-937. 被引量:1
  • 3Furukawa Y, Miki Y. Process for preparing glycidylphtha-limide [ P] : US :6,875,875,2005-04-05. 被引量:1
  • 4Nishiyama Akira. Method for producing optically active N-(3- halo-2-hydroxypropyl ) phthalimide [ P ]: WO: 2007074686, 2007-07-05. 被引量:1
  • 5Artico M, De Martino G, Giuliano R. Research on com- pounds with antiblastic acitvity. XXXIV. derivatives of 3-p- aminophenyl-2-oxazolidinone: synthesis and antineoplastic activities [ J ]. ll Farmaco; edizione scientifica, 1969, 24 (2) :179-190. 被引量:1
  • 6Okano K, Tokuyama H, Fukuyama T. Synthesis of sec- ondary arylamines through copper-mediated intermolecu- lar aryl amination [ J ]. Org lett, 2003,5 (26) : 4 987-4 99O. 被引量:1
  • 7袁静,黄长江,张俊伟,张士俊,徐为人.利伐沙班的合成[J].中国新药杂志,2010,19(23):2185-2187. 被引量:18
  • 8罗玲艳,申东升,周宗洲,谭诚,黄英堂.4-(4-氨基苯基)-3-吗啉酮的合成[J].中国医药工业杂志,2011,42(2):93-95. 被引量:7
  • 9刘薇(编译),董金华(审校).利伐沙班(rivaroxaban)[J].中国药物化学杂志,2011,21(6):508-508. 被引量:5
  • 10庞家莲,蒙光义.利伐沙班临床研究与应用进展[J].内科,2012,7(4):389-391. 被引量:18

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部